WHAT RESEARCHERS STUDY
Primary research interest.
- Appetite and satiety signalling
- Body-weight and metabolic outcomes
- Glycaemic-control pathways
- Liver-fat and cardiometabolic markers
BEST SELLER
METABOLIC RESEARCH · IP-RTR-10
Retatrutide
Metabolic signalling and triple-receptor agonism.
EVIDENCE SNAPSHOT · Human Phase 3 research
Retatrutide is an investigational single molecule that activates GIP, GLP-1 and glucagon receptors. It is being studied in late-stage clinical programs for obesity, overweight and type 2 diabetes.
10 mg / vial$128.00 CAD
FOR LABORATORY RESEARCH USE ONLYNot for human or animal consumption. No dosing or administration information is provided.
COMMUNITY DISCUSSION · ANECDOTAL
What people discuss online.
Reddit discussions most often centre on appetite reduction, earlier fullness and body-weight change. Reports vary widely and include side-effect concerns; these anecdotes are not evidence of safety or effectiveness.
Community reports can be affected by placebo effects, concurrent products, training, diet, selection bias and inaccurate product identity.
EVIDENCE LIMITS
What the page does not claim.
Retatrutide remains investigational and is not an FDA-approved drug. FDA states it has not been found safe and effective for any condition and cannot be used in compounding under U.S. federal law.
SOURCES & FURTHER READING